S11 Ep6: FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer

from OncLive® On Air · host OncLive® On Air

Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Episode metadata supplied by the publisher feed · Published Aug 26, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S11 Ep6: FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer

0:00 8:37

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 8 minutes long.

This episode was published on August 26, 2024.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!